[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100634098":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":33,"responsibleParty":64,"collaborators":68,"id":72,"slug":10,"hasResults":73,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":73,"sex":79,"minAge":80,"maxAge":10,"enrollmentInfo":81,"targetDuration":84,"studyType":85,"phases":10,"briefSummary":86,"conditions":87,"keywords":90,"overallStatus":36,"whyStopped":10,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"Icahn School of Medicine at Mount Sinai","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients indicated for atrial arrhythmia ablation",null,"All patients will receive standard of care treatment.",[13],"Device: FARAWAVE Pulsed Field Ablation Catheter",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DEVICE","FARAWAVE Pulsed Field Ablation Catheter","The FARAWAVE Pulsed Field Ablation (PFA) Catheter is a component of the FARAPULSE PFA System. The FARAWAVE Catheter is an over-the-wire, multi-electrode catheter designed to deliver PFA energy to the distal section for cardiac ablation. The FARAWAVE Catheter is indicated for: 1) the isolation of pulmonary veins in the treatment of drug-refractory, recurrent, symptomatic Paroxysmal Atrial Fibrillation (PAF) 2) the isolation of pulmonary veins and the posterior wall in the treatment of drug-refractory, symptomatic Persistent Atrial Fibrillation (episode duration less than one year) This device is FDA approved.",[9],[21],{"name":22,"affiliation":5,"role":23},"Vivek Reddy, MD","PRINCIPAL_INVESTIGATOR",[25,30],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},"Devin Chamberlain","CONTACT","(646) 984-1049","devin.chamberlain@mountsinai.org",{"name":31,"role":27,"phone":10,"phoneExt":10,"email":32},"Betsy Ellsworth, MSN, ANP","Betsy.ellsworth@mountsinai.org",[34,50],{"facility":35,"status":36,"city":37,"state":37,"zip":38,"country":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"The Mount Sinai Hospital","RECRUITING","New York","10030","United States",{"type":41,"coordinates":42},"Point",[43,44],-74.00597,40.71427,{"lat":44,"lon":43},[47,48],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},{"name":49,"role":23,"phone":10,"phoneExt":10,"email":10},"Joshua Lampert, MD",{"facility":51,"status":36,"city":52,"state":53,"zip":54,"country":39,"cosmosGeoPoint":55,"geoPoint":59,"contacts":60},"Valley Health System","Winchester","Virginia","22601",{"type":41,"coordinates":56},[57,58],-78.16333,39.18566,{"lat":58,"lon":57},[61],{"name":62,"role":27,"phone":10,"phoneExt":10,"email":63},"Lauren Peterson","lpeterso@valleyhealthlink.com",{"type":65,"investigatorFullName":66,"investigatorTitle":67,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","Vivek Reddy","Director, Cardiac Arrhythmia Service",[69],{"name":70,"class":71},"Boston Scientific Corporation","INDUSTRY","100634098",false,"NCT07535268","REPRESENT-PF Registry","Prospective Multicenter Registry on the Clinical Outcomes and Safety of PFA for Atrial Fibrillation in Underrepresented Minorities (REPRESENT-PF Registry)","REPRESENT-PF","Inclusion Criteria:\n\n* All consecutive patients classified as racial or ethnic minorities undergoing ablation using Boston Scientific FDA approved PFA catheters for AF will be included.\n* De novo ablation for symptomatic paroxysmal and persistent AF (Age ≥ 18) (unless it is a repeat for a patient whose index procedure is also in the registry) who are deemed to be candidates for AF ablation by the investigator.\n* Able and willing to participate in baseline and follow up evaluation over the study period\n* Willing and able to provide informed consent, if applicable.\n\nExclusion Criteria:\n\n* Enrolled in an investigational drug or device clinical trial or any other trial with outlined treatment plan\n* Long standing persistent AF (AF \\> 1 year duration)\n* Repeat ablation, unless index ablation procedure was in the REPRESENT-PF registry\n* Any known contra-indication to ablation procedure at the discretion of the investigator","ALL","18 Years",{"count":82,"type":83},275,"ESTIMATED","12 Months","OBSERVATIONAL","This pragmatic, prospective, single-arm, multi-center, observational registry will evaluate the safety and effectiveness of PFA for the treatment of atrial fibrillation in underrepresented minority patients using FDA approved Boston Scientific PFA catheters; all data collected will be standard of care.",[88,89],"Persistent Atrial Fibrillation","Paroxysmal Atrial Fibrillation",[89,88,91],"Pulsed Field Ablation","2026-04-09",{"date":94,"type":95},"2026-04-17","ACTUAL",{"date":97,"type":95},"2026-03-30",{"date":99,"type":83},"2028-03-01",{"name":66,"class":6},2]